CAROLINE GHEE: Open Payments
NPI 1558072108 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,516 in 68 payments from 18 companies in 2025. Trend: 2023 $318 · 2024 $854 · 2025 $1,516
Food & beverage: $1,516
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 11 | $220 |
| PFIZER INC. | 8 | $208 |
| GENZYME CORPORATION | 7 | $193 |
| Janssen Biotech, Inc. | 8 | $155 |
| ABBVIE INC. | 9 | $136 |
| Amgen Inc. | 5 | $123 |
| Lilly USA, LLC | 4 | $101 |
| Incyte Corporation | 3 | $70 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $53 |
| Novartis Pharmaceuticals Corporation | 2 | $47 |
Products named: CIBINQO, DUPIXENT, TREMFYA, OTEZLA, SKYRIZI, TALTZ, OPZELURA, NEMLUVIO.
Industry payments across DC — which companies pay providers there.
